All articles by Adam Zamecnik

Adam Zamecnik is a healthcare reporter for Pharmaceutical Technology. He has covered diverse topics such as continuous drug manufacturing, genomic research and sexual health. He is particularly interested in new technologies, health inequality, and cell and gene therapy research.

Adam Zamecnik


EU agencies back Covid-19 vaccine update ahead of autumn campaign

Two EU agencies issued a statement on Covid-19 vaccine composition changes to include XBB Omicron variants for use in key patient groups.

ASCO 2023: Janssen’s Carvykti wins in earlier treatment of multiple myeloma

The abstract featured data from the Phase III CARTITUDE-4 trial, paving the way for Carvykti’s use in earlier lines of treatment.

ITM raises $273 million to fund radionuclide therapy pipeline

Described as one of the largest rounds in Germany, the funding will power pipeline development alongside manufacturing capacities.

Q&A: How Big Pharma implements analytics in continuous manufacturing

Allan Myerson talks about the latest advances in the adoption of continuous manufacturing and the use of analytical processes in the field.

Pneumagen raises £8 million for further study of intranasal antiviral

The Scottish company raised further funding to fuel an upcoming Phase IIb study of its compound neumifil in COPD patients.

Anocca raises over $36 million for cancer cell therapy studies

The latest round adds to past funding intended to move the company’s candidates into early clinical studies, with a trial planned for 2024.

AstriVax received €2.5 million government grant for thermostable vaccines

The Flemish government grant adds on past seed funding that will be used to move the company’s thermostable vaccines to the clinic.

Immuno-oncology market set to grow in billions, but access concerns remain

The immune-oncology market is forecasted to grow to over $150 billion by 2028, based on a recent GlobalData webinar.

UK agency pilots biobank to study links between genetics and drug side effects

The MHRA will launch the Yellow Card biobank in collaboration with Genomics England to study the link between genetics and adverse events.

US government plans proposal to push down Medicaid drug prices

The Department of Health and Human Services details new plans to survey drug costs and transparency measures to save Medicaid spending.